Urinary Incontinence – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Urinary Incontinence – Pipeline Review, H2 2019’, provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence

– The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects

– The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Urinary Incontinence”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

FemmePharma Global Healthcare Inc

Innovacell Biotechnologie AG

Pfizer Inc

Revance Therapeutics Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Urinary Incontinence Overview

Urinary Incontinence Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence Companies Involved in Therapeutics Development

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Pfizer Inc

Revance Therapeutics Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC

Urinary Incontinence Drug Profiles

abobotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-hs Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Urinary Incontinence Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gtx-027 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICES-13 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

litoxetine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-352 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NET for Stress Urinary Incontinence Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolterodine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Urinary Incontinence Dormant Projects

Urinary Incontinence Discontinued Products

Urinary Incontinence Product Development Milestones

Featured News & Press Releases

Jan 11, 2018: Sleep quality improves with help of incontinence drug

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting

Oct 09, 2013: Allergan’s BOTOX (Botulinum Toxin Type A) Recommended by the Scottish Medicines Consortium for the Management of Detrusor Overactivity with Urinary Incontinence (Leakage) in Patients with Multiple Sclerosis or Spinal Cord Injury

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg

Nov 06, 2012: Beech Tree Labs Completes Phase IIa Urinary Incontinence Clinical Trial Using UISH001

Sep 27, 2012: Allergan's Botox Receives UK Authorization For Urinary Leakage In Patients With Multiple Sclerosis Or Spinal Cord Injury

Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference

Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency

Aug 30, 2011: Innovacell passes a further milestone

Aug 24, 2011: Allergan Receives FDA Approval For Botox For Treatment Of Urinary Incontinence In Adults With Neurological Conditions

Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Urinary Incontinence, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Urinary Incontinence – Pipeline by Allergan Plc, H2 2019

Urinary Incontinence – Pipeline by Beech Tree Labs Inc, H2 2019

Urinary Incontinence – Pipeline by Crystec Ltd, H2 2019

Urinary Incontinence – Pipeline by FemmePharma Global Healthcare Inc, H2 2019

Urinary Incontinence – Pipeline by Innovacell Biotechnologie AG, H2 2019

Urinary Incontinence – Pipeline by Pfizer Inc, H2 2019

Urinary Incontinence – Pipeline by Revance Therapeutics Inc, H2 2019

Urinary Incontinence – Pipeline by Saniona AB, H2 2019

Urinary Incontinence – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019

Urinary Incontinence – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Urinary Incontinence – Pipeline by Taris Biomedical LLC, H2 2019

Urinary Incontinence – Dormant Projects, H2 2019

Urinary Incontinence – Dormant Projects, H2 2019 (Contd..1), H2 2019

Urinary Incontinence – Dormant Projects, H2 2019 (Contd..2), H2 2019

Urinary Incontinence – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Urinary Incontinence, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports